Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, Moshe Ben-Shoshan, Ana M. Giménez-Arnau, Jonathan A. Bernstein, Akiko Yagami, Aleksandra Stjepanovic, Allen Radin, Heribert W. Staudinger, Naimish Patel, Nikhil Amin, Bolanle Akinlade, Chunpeng Fan, Deborah Bauer, George D. Yancopoulos, Kiran Patel, Leda P. Mannent, Elizabeth Laws

研究成果: ジャーナルへの寄稿学術論文査読

4 被引用数 (Scopus)

抄録

Background: Chronic spontaneous urticaria (CSU) is a chronic inflammatory disease characterized by recurrent pruritic wheals (hives) and/or angioedema. Patients with CSU could remain symptomatic despite standard-of-care H1 antihistamines (H1-AH) or anti-IgE (omalizumab) treatment. Dupilumab blocks IL-4/IL-13 signaling and is approved for multiple type 2/atopic indications. Objective: We conducted two phase 3, randomized, placebo-controlled, double-blind trials comparing dupilumab with placebo in patients with symptomatic CSU despite H1-AH. Methods: In LIBERTY-CSU CUPID Study A, patients were omalizumab-naive (n = 138, aged ≥6 years). In Study B, patients were omalizumab-intolerant/incomplete responders (n = 108, aged ≥12 years). The primary end point was either change from baseline over 7 days in the Urticaria Activity Score (UAS7) or Itch Severity Score (ISS7) at week 24, with the other as a key secondary end point, depending on regional regulatory requirements. Studies were pooled for safety assessment. Results: In Study A, UAS7 and ISS7 improved with dupilumab versus placebo (difference −8.5 [95% CI, −13.2 to −3.9; P = .0003] and −4.2 [95% CI, −6.6 to −1.8; P = .0005]). In Study B, tested at α = 0.043 after interim analysis, UAS7 improved (difference −5.8 [95% CI, −11.4 to −0.3; P = .0390]), with a numerical trend in ISS7 (difference −2.9 [95% CI, −5.7 to −0.07; nominal P = .0449, not significant]). Pooled safety data were consistent between dupilumab and placebo and with the known dupilumab safety profile. Conclusions: Dupilumab reduced urticaria activity by reducing itch and hives severity in omalizumab-naive patients with CSU uncontrolled with H1-AH. Although the primary end point for Study B was not met, dupilumab effects were small in patients who were omalizumab-intolerant/incomplete responders.

本文言語英語
ジャーナルJournal of Allergy and Clinical Immunology
DOI
出版ステータス印刷中 - 2024

All Science Journal Classification (ASJC) codes

  • 免疫アレルギー学
  • 免疫学

フィンガープリント

「Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル